Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13036980 | 1.00 | KDM4E (0.39) | KDM4EBCHEACHEHSD17B10L3MBTL1 | |
| SCHEMBL14671205 | 0.89 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2 | |
| SCHEMBL18843668 | 0.86 | HSD17B10 (0.40) | KDM4EHSD17B10ALDH1A1 | |
| SCHEMBL13036979 | 0.84 | BCHE (0.41) | KDM4EBCHEACHEL3MBTL1ALDH1A1 | |
| SCHEMBL12424611 | 0.84 | BCHE (0.41) | KDM4EBCHEACHEL3MBTL1ALDH1A1 | |
| SCHEMBL13036974 | 0.83 | CYP1A2 (0.41) | KDM4EBCHEOPRL1OGFRL1ALDH1A1 | |
| SCHEMBL11811902 | 0.83 | CYP1A2 (0.41) | KDM4EBCHEOPRL1OGFRL1ALDH1A1 | |
| SCHEMBL16905075 | 0.81 | KDM4E (0.42) | KDM4EL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL13036981 | 0.80 | KDM4E (0.44) | KDM4EBCHEACHEALDH1A1MEN1 | |
| SCHEMBL13036976 | 0.80 | CYP1A2 (0.54) | BCHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9668973-B2 | Components for producing amphoteric liposomes | MARINA BIOTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2015106164-A1 | LXR AGONISTS AND USES THEREOF | RGENIX, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20140227345-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | MARINA BIOTECH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-7407947-B2 | Amphoteric sterols and the use thereof | NOVOSOM AG (DE) | 2008-08-05 | — | — | US | disclosed |
| EP-0931078-B1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-5965570-A | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE ABNORMAL GROWTH OF CELLS; ADMINISTERING TO INHIBIT TUMOR CELLS WHEREIN THE RAS PROTEIN IS ACTIVATED AS A RESULT OF ONCOGENIC MUTATION IN GENES OTHER THAN THE RAS GENE | SCHERING CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0931078-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998011098-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-03-19 | — | — | WO | disclosed |
| US-4012396-A | Processes and intermediates for cis or trans 2-or 3-(1-acyl-3-vinyl-4-piperidine)acetic or propionic acid esters | HOFFMANN-LA ROCHE INC. (US) | 1977-03-15 | — | — | US | disclosed |
| US-3959294-A | Processes and intermediates for cis or trans 2- or 3-(1-acyl-3-vinyl-4-piperidine)acetic or propionic acid esters | HOFFMANN-LA ROCHE INC. (US) | 1976-05-25 | — | — | US | disclosed |
| US-3957800-A | PROCESSES AND INTERMEDIATES FOR CIS OR TRANS 2- OR 3-(1-ACYL-3-VINYL-4-PIPERIDINE)ACETIC OR PROPIONIC ACID ESTERS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227345-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | PHOSPHO1, SGMS1, CHMP4B | KDM4E 2892/4885BCHE 2197/4885ACHE 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.